Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
Is there any reason to use GnRH agonists in patients with metastatic prostate cancer after bilateral orchiectomy?
Related Questions
How do you manage drug-drug interactions between oral anticoagulants and the ARSI agents such as apalutamide and enzalutamide?
In a patient with very high risk prostate cancer opting for prostatectomy, when, if ever, do you recommend neoadjuvant ADT?
How do you interpret PSMA/PET with focal prostate activity after XRT currently on ADT with stable PSA?
What is your approach to systemic treatment of de novo metastatic hormone-sensitive prostate ductal adenocarcinoma with lung only metastases?
How do you manage de novo high volume mCSPC with both BRCA2 mutation and MSI-H on somatic testing?
What is the optimal sequence of available therapies in patients with BRCA+/HRR mCRPC after progression on first line combinations?
Would you consider adding abiraterone to ADT and salvage RT in a prostate cancer patient with pN1 disease at radical prostatectomy?
Is there any way to safely treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?
Can you/do you use an androgen receptor blocker alone in patients with metastatic hormone-sensitive prostate cancer who cannot tolerate GnRH-directed therapy?
Would you consider adding abiraterone, in addition to ADT, for patients with less than very-high risk localized prostate cancer but high clinical-genomic metastasis risk after EBRT?
